Pharmaceuticals
turnover in the six months was £8,465 million, up 3% AER, 1%
CER. Respiratory sales were up 21% AER, 17% CER, to
£1,383 million, on growth of
Trelegy
Ellipta
and
Nucala
. HIV sales were up 4% AER,
1% CER, to £2,330 million, with growth in
Juluca
and
Dovato
partly offset by a decline
in
Triumeq
.
Sales of Established Pharmaceuticals declined 6% AER, 7% CER to
£4,380 million including the impact of loss of exclusivity
of
Advair
.
In the
US, sales grew 1% AER but declined 5% CER. Continued growth
of
Nucala
,
Trelegy
Ellipta
and
Benlysta
was offset by the decline
in Established Products including the loss of exclusivity
of
Advair
and
in
Relvar/Breo
Ellipta
, impacted by genericisation of the ICS/LABA
market. In Europe, sales grew 1% AER, 1% CER, with strong
growth in Respiratory partly offset by a decline in Established
Pharmaceuticals. International grew 6% AER, 6% CER, with
growth in all therapy areas.
Respiratory
Total
Respiratory sales were up 21% AER, 17% CER, with strong growth in
all regions.
Ellipta
product sales grew 16%
AER, 12% CER, with Europe up 28% AER, 29% CER and International up
32% AER, 31% CER on
Trelegy
Ellipta
and
Relvar/Breo
Ellipta
growth.
Nucala
was up 45% AER, 45% CER in
Europe and 55% AER, 52% CER in International. In the
US,
Trelegy
Ellipta
and
Nucala
growth offset the decline
in
Relvar/Breo
Ellipta
on post-generic ICS/LABA price
pressure.
Sales
of
Nucala
were
£347 million in the six months and grew 42% AER, 37% CER,
continuing to benefit from the global rollout of the product.
US sales of
Nucala
grew 37% AER, 30% CER to
£202 million.
Sales
of
Ellipta
products were up 16% AER,
12% CER to £1,036 million driven by growth in Europe and
International. In the US, sales grew 6% AER but were flat at
CER, reflecting continued competitive pricing pressures for
ICS/LABA products post generic
Advair
. In Europe, sales grew 28%
AER, 29% CER, and in International by 32% AER, 31% CER. Sales
of
Trelegy Ellipta
,
our new once daily closed triple product, contributed £207
million globally in the six months, continuing to benefit from the
expanded US label.
Relvar/Breo Ellipta
sales were down 9% AER, 11%
CER. This was driven by the US decline of 33% AER, 37% CER,
impacted by US competitive pricing pressures and the impact of
generic
Advair
on
the US ICS/LABA market. In Europe and
International,
Relvar/Breo
Ellipta
continued to grow, up 11% AER, 12% CER, and 22%
CER, 20% AER, respectively.
HIV
HIV
sales grew 4% AER, 1% CER to £2,330 million in the six months
to June. The dolutegravir franchise grew 7% AER, 3% CER,
delivering sales of £2,214 million in the six months.
The remaining portfolio with sales of £116 million, 5% of
total HIV sales, declined 28% AER, 28% CER and reduced the overall
growth of total HIV by 3% AER, 2% CER in the six months to
June.
Sales
of dolutegravir products were £2,214 million in the six
months, with
Triumeq
and
Tivicay
delivering sales of
£1,260 million and £795 million, respectively. The
two-drug regimens
Juluca
and
Dovato
delivered sales of
£159 million in the six months to June. The combined
growth of the two-drug regimens offset the decline in the
three-drug regimen,
Triumeq
, as the business transitions to
the new portfolio.
In the
US, the second two-drug regimen,
Dovato
, was launched in April 2019,
which, combined with
Juluca
, delivered sales of £136
million. Total dolutegravir sales grew 4% AER but declined 1%
CER reflecting the share decline in
Tivicay
and
Triumeq
, partly offset by the share
gain on two-drug regimens as the business transitions to the new
portfolio. In Europe, overall dolutegravir sales growth was
flat at both AER and CER with growth in dolutegravir share offset
by price erosion, and the timing of clawback payments.
International grew strongly with overall dolutegravir sales
growth of 37% AER, 38% CER, driven by
Tivicay
and
Triumeq
.
Oncology
Sales
of
Zejula
, were
£99 million in the period from the date of acquisition,
comprising £59 million in the US and £40 million in
Europe.
Immuno-inflammation
Sales
of
Benlysta
in
the six months were up 27% AER, 21% CER to £271 million,
including sales of the sub-cutaneous formulation. In the
US,
Benlysta
grew
24% AER, 18% CER to £237 million.
Established Pharmaceuticals
Sales
of Established Pharmaceuticals in the six months were £4,380
million, down 6% AER, 7% CER.
Established
Respiratory products declined 6% AER, 8% CER to £1,996
million, with the decline in
Seretide/Advair
partially offset
by higher sales of
Ventolin
and allergy
products. In the US, a generic version of
Advair
was launched in February,
resulting in a 43% AER, 45% CER decline in the six months. In
Europe,
Seretide
sales were down 17% AER,
17% CER to £262 million, reflecting continued competition from
generic products and the transition of the Respiratory portfolio to
newer products. In International, sales of
Seretide
grew 1% AER, 2% CER.
Globally,
Ventolin
grew by 37% AER, 34% CER
driven by the strong uptake of an authorised generic version in the
US.
The
remainder of the Established Pharmaceuticals portfolio declined 5%
AER, 5% CER broadly in line with the underlying mid single-digit
decline expected of this portfolio.
|